Course of distress, anxiety, and depression in hematological cancer patients: Association between gender and grade of neoplasm

2013 ◽  
Vol 13 (2) ◽  
pp. 115-123 ◽  
Author(s):  
Cristiane Decat Bergerot ◽  
Karen Lynn Clark ◽  
Alexandre Nonino ◽  
Sarah Waliany ◽  
Marco Murilo Buso ◽  
...  
Keyword(s):  
Significant Interaction ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Hematological Cancer ◽  
Physical Problems ◽  
Male Patients ◽  
A Prospective Study ◽  
The Impact ◽  
Over Time

AbstractObjective:The aim of our study was to explore the impact of gender and hematological cancer grade on distress, anxiety, and depression in patients receiving chemotherapy.Methods:A prospective study was done in a cohort of 104 patients with hematological cancer. We employed the (1) Distress Thermometer (DT) and the Problem List (PL) and (2) the Hospital Anxiety and Depression Scale (HADS) for assessments at baseline (T1), the halfway timepoint (T2), and completion of chemotherapy (T3).Results:The proportion of patients experiencing significant distress (DT ≥ 4) decreased from the first to the last timepoint; the proportion experiencing anxiety and depression (as assessed by HADS) also decreased. Specifically, 50% of participants reported significant distress levels, 47.1% anxiety, and 26% depression at T1. At T2, the proportion of patients experiencing distress was reduced by 60.8%, by 76% for anxiety, and by 48.5% for depression; at T3, the reduction was close to 80% for all assessments compared with T1. Emotional and physical problems were most commonly reported. Significant reductions were discovered for distress and problem-related distress levels over time, and a significant interaction was found between gender and practical and physical problems (p < 0.05).Significance of results:Our findings suggest that female patients reported more distress, anxiety, and depression than male patients. Gender differences were related to problem-related distress but not to grade of neoplasm. We observed that, over the course of chemotherapy, the distress levels of patients with hematological cancer decrease over time.

scholarly journals Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers

2020 ◽  
Vol 7 (5) ◽  
pp. 490-497
Author(s):  
Deborah A Forst ◽  
Kit Quain ◽  
Sophia L Landay ◽  
Maya Anand ◽  
Emilia Kaslow-Zieve ◽  
...  
Keyword(s):  
Malignant Gliomas ◽  
Depression Scale ◽  
Primary Treatment ◽  
Treatment Goal ◽  
Anxiety And Depression ◽  
Newly Diagnosed ◽  
Hospital Anxiety ◽  
Treatment Perceptions ◽  
Multivariable Regression ◽  
A Prospective Study

Abstract Background Patients with malignant gliomas have a poor prognosis. However, little is known about patients’ and caregivers’ understanding of the prognosis and the primary treatment goal. Methods We conducted a prospective study in patients with newly diagnosed malignant gliomas (N = 72) and their caregivers (N = 55). At 12 weeks after diagnosis, we administered the Prognosis and Treatment Perceptions Questionnaire to assess understanding of prognosis and the Hospital Anxiety and Depression Scale to evaluate mood. We used multivariable regression analyses to explore associations between prognostic understanding and mood and McNemar tests to compare prognostic perceptions among patient-caregiver dyads (N = 48). Results A total of 87.1% (61/70) of patients and 79.6% (43/54) of caregivers reported that it was “very” or “extremely” important to know about the patient’s prognosis. The majority of patients (72.7%, [48/66]) reported that their cancer was curable. Patients who reported that their illness was incurable had greater depressive symptoms (B = 3.01, 95% CI, 0.89-5.14, P = .01). There was no association between caregivers’ prognostic understanding and mood. Among patient-caregiver dyads, patients were more likely than caregivers to report that their primary treatment goal was cure (43.8% [21/48] vs 25.0% [12/48], P = .04) and that the oncologist’s primary goal was cure (29.2% [14/48] vs 8.3% [4/48], P = .02). Conclusions Patients with malignant gliomas frequently hold inaccurate perceptions of the prognosis and treatment goal. Although caregivers more often report an accurate assessment of these metrics, many still report an overly optimistic perception of prognosis. Interventions are needed to enhance prognostic communication and to help patients cope with the associated distress.

Is alexithymia a personality trait increasing the risk of depression? A prospective study evaluating alexithymia before, during and after a depressive episode

2008 ◽  
Vol 38 (12) ◽  
pp. 1717-1722 ◽  
Author(s):  
C. Marchesi ◽  
S. Bertoni ◽  
A. Cantoni ◽  
C. Maggini
Keyword(s):  
Prospective Study ◽  
Pregnant Women ◽  
Personality Trait ◽  
Depressive Episode ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
State Dependent ◽  
A Prospective Study ◽  
Care Evaluation

BackgroundWhether alexithymia is a personality trait that increases the risk of major depression (MD) is still debated. In this prospective study, alexithymic levels were evaluated before, during and after a depressive episode.MethodThe alexithymic levels, the presence of MD and the severity of anxious-depressive symptoms were evaluated at intervals of about 1 month in pregnant women attending the Centers for Prenatal Care, using the Toronto Alexithymia Scale (TAS), the Primary Care Evaluation of Mental Disorders (PRIME-MD) and the Hospital Anxiety and Depression Scale (HADS).ResultsSixteen women affected by MD, 21 affected by subthreshold depression and 112 non-depressed women were included in the study. Women who developed depression, compared to non-depressed women, showed similar TAS and HADS scores during the pre-morbid phase, a significant increase in the scores during depression and a significant decrease after remission, whereas no change was observed in non-depressed women.ConclusionsOur data suggest that in pregnant women alexithymia does not represent a personality trait that increases the risk of developing a depressive episode, and they support the hypothesis that alexithymia is a state-dependent phenomenon in depressed pregnant women.

scholarly journals Cognitive Impairment after Severe Traumatic Brain Injury, Clinical Course and Impact on Outcome: A Swedish-Icelandic Study

2015 ◽  
Vol 2015 ◽  
pp. 1-12 ◽  
Author(s):  
Maud Stenberg ◽  
Alison K. Godbolt ◽  
Catharina Nygren De Boussard ◽  
Richard Levi ◽  
Britt-Marie Stålnacke
Keyword(s):  
Cognitive Function ◽  
Clinical Course ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Early Screening ◽  
Multicenter Observational Study ◽  
Severe Tbi ◽  
Prospective Multicenter Observational Study ◽  
Over Time

Objective. To assess the clinical course of cognitive and emotional impairments in patients with severe TBI (sTBI) from 3 weeks to 1 year after trauma and to study associations with outcomes at 1 year.Methods. Prospective, multicenter, observational study of sTBI in Sweden and Iceland. Patients aged 18–65 years with acute Glasgow Coma Scale 3–8 were assessed with the Barrow Neurological Institute Screen for Higher Cerebral Functions (BNIS) and the Hospital Anxiety and Depression Scale (HADS). Outcome measures were Glasgow Outcome Scale Extended (GOSE) and Rancho Los Amigos Cognitive Scale-Revised (RLAS-R).Results. Cognition was assessed with the BNIS assessed for 42 patients out of 100 at 3 weeks, 75 patients at 3 months, and 78 patients at 1 year. Cognition improved over time, especially from 3 weeks to 3 months. The BNIS subscales “orientation” and “visuospatial and visual problem solving” were associated with the GOSE and RLAS-R at 1 year.Conclusion. Cognition seemed to improve over time after sTBI and appeared to be rather stable from 3 months to 1 year. Since cognitive function was associated with outcomes, these results indicate that early screening of cognitive function could be of importance for rehabilitation planning in a clinical setting.

scholarly journals Gender differences in coping styles of patients with depression: A comparative study

2018 ◽  
Vol 27 (2) ◽  
pp. 145-154
Author(s):  
Anita Rani Saha ◽  
Farah Deeba
Keyword(s):  
Gender Differences ◽  
Coping Style ◽  
Coping Styles ◽  
Depression Scale ◽  
Sampling Technique ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Study Results ◽  
Male Patients ◽  
Convenience Sampling

The present study was undertaken to investigate the gender differences in coping styles of patient with depression. Three types of coping styles were measured: problem focused, emotion focused and dysfunctional copings. The sample consisted of 101 participants (Male = 61, 60.4%) and (Female = 40, 39.6%) diagnosed with depression who were selected through convenience sampling technique from different hospitals of Dhaka city. Depression scale (DS), adapted Bengali version of Hospital Anxiety and Depression Scale (HADS) and adapted Bengali version of COPE scale were used to assess different variables for the present study. Results of the study indicated that male patients were tending to use more problem focused coping styles than females and female patients were tending to use more dysfunctional coping style than male. There was no gender difference found in the groups on emotion focused coping style. Based on the findings developing a better therapeutic intervention to treat depression, was discussed. Dhaka Univ. J. Biol. Sci. 27(2): 145-154, 2018 (July)

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

2013 ◽  
Vol 20 (1) ◽  
pp. 108-111 ◽  
Author(s):  
Johannis A van Rossum ◽  
Anke Vennegoor ◽  
Lisanne Balk ◽  
Bernard M Uitdehaag ◽  
Chris H Polman ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Jc Virus ◽  
Depression Scale ◽  
Decisional Conflict ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Analog Scale ◽  
Natalizumab Treatment ◽  
Calculated Risk ◽  
The Impact

The use of natalizumab in multiple sclerosis has been restricted by the risk of progressive multifocal leukoencephalopathy (PML). JC virus carriership, duration of natalizumab treatment and past immunosuppression are known risk factors. This has allowed for calculated risk assessment for individual patients to be implemented. Not much data are available about the effect of JCV carriership on patient willingness to continue natalizumab. Here, we evaluated the impact of JCV seropositivity on safety feelings, anxiety and treatment continuation for patients treated with natalizumab, using a visual analog scale, the Hospital Anxiety and Depression Scale and a decisional conflict scale. Seropositivity led to an elevated anxiety level for PML ( p = 0.004). However, so far only 3% of patients have discontinued natalizumab because of JCV positivity in our cohort.

scholarly journals Gender and Time-Related Differences in a Large Cohort of Heavy Smokers Applying for Treatment to a Tobacco Centre in Italy

2017 ◽  
Vol 13 (3) ◽  
pp. 121-128
Author(s):  
Carlotta Defferrari ◽  
Cristina Barbara ◽  
Matteo Puntoni ◽  
Marilena Petrera ◽  
Stefano Domenicucci ◽  
...  
Keyword(s):  
Nicotine Dependence ◽  
Depression Scale ◽  
Psychological Characteristics ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Quit Smoking ◽  
Clinically Depressed ◽  
Study Population ◽  
Over Time

Introduction: Attempts to quit smoking have increased in recent years, but the patterns of variations over time are unknown. We aimed at describing time- and sex-related changes in a population of 2,231 subjects who adhered to a smoking-cessation programme lasting 13 years in Italy.Methods: We measured baseline expired carbon monoxide (expired-CO), Fagerstrom nicotine dependence, Q-MAT test, Zung depression and anxiety scale, Hospital anxiety and depression scale (HADS).Results: Study population included 1,278 men and 953 women who smoked a median of 25 (interquartile range, IQR: 20–32) and 20 (IQR: 20–30) cigarettes/day, respectively (p < 0.001). The proportion of female smokers increased from 37.5% in 2001–2003 to 46.9% in 2010–2013 (p = 0.003). There was a significant time-related reduction of median daily cigarette consumption, with a more noticeable decrease in men. Median expired-CO (parts per million (ppm)) increased only in women, from 18 (IQR: 14–23) in 2001–03 to 20 (IQR: 14–28) in 2010–13 (p = 0.001), whereas Fagerstrom test for nicotine dependence did not vary. Differences in psychological characteristics in the last 3 years showed that women were more clinically depressed than men (16.6% versus 7.6%, p < 0.001).Conclusions: Despite a decrease in the number of daily cigarettes with time, expired-CO tends to increase in women, who are also more clinically depressed and anxious than men. A personalised approach to specific subgroups of smokers, with special emphasis on a psychological support for women, seems appropriate.

Emotional disclosure in home hospice cancer care: Implications for spouse caregiver bereavement.

2016 ◽  
Vol 34 (26_suppl) ◽  
pp. 54-54
Author(s):  
Maija Reblin ◽  
Lee Ellington ◽  
Margaret Clayton ◽  
Michael Caserta ◽  
Dale Lund ◽  
...  
Keyword(s):  
Emotional Response ◽  
Positive Emotion ◽  
Interaction Analysis ◽  
Depression Scale ◽  
Emotional Disclosure ◽  
Anxiety And Depression ◽  
Patient Death ◽  
Emotion Talk ◽  
The Impact ◽  
Over Time

54 Background: Evidence shows the benefit of positive and negative emotional disclosure for family caregivers (CG), but little is known about the impact of emotional disclosure at end of life. We assessed the effect of CG and hospice nurse disclosure during home visits on CG anxiety and depression in bereavement. Methods: As part of a larger study, nurse visits to 95 spouse CGs of cancer home hospice patients were audio recorded. An adapted Roter Interaction Analysis System was used to identify emotional disclosure: CG and nurse positive emotion (humor, gratitude), CG distress, and nurse emotional response (reassurance, validation). CGs completed demographics at hospice enrollment, and HADS anxiety scale, and Geriatric Depression Scale (GDS) at enrollment, and 2, 6 and 12 months after patient death. Growth curve analysis was conducted to predict HADS and GDS trajectories, controlling for CG gender, total talk, anxiety and depression at enrollment. Results: Average spouse CG age was 65; 60% were female and 98% were white. There were no GDS effects for CG expression of distress or nurse emotional response. Higher CG positive emotion talk predicted higher GDS at 2 months (B = .18, p < .01), but a significant decline of GDS over time (B = -.08, p = .03). There were no effects for CG emotional disclosure on anxiety. However, more nurse emotional response predicted lower anxiety at 2 months (B = -.10, p = .02) which did not significantly change over time. More nurse positive emotion did not impact anxiety at 2 months, but predicted lower anxiety over time (B = -.04, p = .04). Conclusions: Emotional disclosure during cancer hospice visits was associated with spouse CG bereavement trajectories. CG positive emotion talk may signal increased potential for depression early in bereavement, but appears to lessen over time. CGs who express more positive emotion, which includes humor, gratitude and savoring the moment, may be more sensitive to loss, but appear to recover in time. Nurse expression of reassurance and validation, and of positive emotions seems to be effective in addressing and normalizing CG anxiety during bereavement. These findings have potential implications for communication interventions.

Assessment of the impact of the Hospital Anxiety and Depression Scale on the initiation of treatment in newly diagnosed cancer patients in a safety-net hospital.

2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 250-250
Author(s):  
Daulath Singh ◽  
Annapoorna Singh ◽  
Punita Grover ◽  
Mahathi Indaram ◽  
Nikki Malomo ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Poisson Regression ◽  
Treatment Initiation ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
P Value ◽  
Newly Diagnosed ◽  
Hospital Anxiety ◽  
Poisson Regression Analysis ◽  
The Impact

250 Background: Distress is a universal symptom in oncologic patients which negatively impact the quality of life and survival. It interferes with the ability to cope with the diagnosis and is a risk factor for non-adherence with treatment. The Hospital Anxiety and Depression Scale (HADS), is used at our institution for distress screening. The aim of our study is to assess the impact of distress, measured by the HADS score, on initiation of treatment in newly diagnosed cancer patients. Methods: We conducted a retrospective chart review of patients with a new diagnosis of cancer, between March 1st, 2014 and December 31st, 2015; who had been evaluated for distress at their first oncology clinic visit. We included only patients who were treated with chemotherapy or chemoradiation, with curative intent. Poisson regression analysis was conducted to investigate the relationship between HADS to treatment initiation while including age, sex, race, insurance status, cancer type, and stage as covariates in the model. Results: A total of 101 patients met the inclusion criteria. The mean age was 54 years, 63% were female and 37% were male. The majority were Caucasians (53%), followed by African-Americans (36%). 56% of the population had Medicaid, and 26% had Medicare and private insurance. The most common cancers were – breast (30%), gastrointestinal (20%), gynecologic (15%) and lung (11%). 64% received chemotherapy and 36% were treated with chemoradiation. We grouped patients into 3 categories based on the HADS score – category 1 with score ≤7 (28%), category 2 with score 8-10 (17%) and category 3 with score ≥11 (55%). The median time to treatment initiation was 28 days. Multivariate Poisson regression analysis did not show any correlation between the HADS score and treatment initiation. Subscales analyses showed that higher depression scores correlate with a delay in treatment initiation (p-value 0.01), while the anxiety scores had no influence (p-value 0.57). Conclusions: In our study, the initial total HADS score did not affect the treatment initiation. Interestingly, depression had an influence on the initiation of treatment in newly diagnosed cancer patients.

scholarly journals Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak

2021 ◽  
Vol 10 (15) ◽  
pp. 3270
Author(s):  
Lorenzo Bertani ◽  
Brigida Barberio ◽  
Domenico Tricò ◽  
Federico Zanzi ◽  
Daria Maniero ◽  
...  
Keyword(s):  
Depression Scale ◽  
Anxiety And Depression ◽  
Disease Relapse ◽  
Hospital Anxiety ◽  
Drug Infusion ◽  
Bowel Diseases ◽  
Risk Of Disease ◽  
Inflammatory Bowel ◽  
Immunomodulatory Therapies ◽  
The Impact

During the coronavirus disease 2019 (COVID-19) pandemic, immunomodulatory therapies and hospital admission were suspected to increase the risk of infection. Nevertheless, patients with inflammatory bowel diseases (IBD) treated with intravenous (i.v.) biologics had to move to hospitals for drug infusion. We investigated the impact of hospitalisation in patients with IBD. We conducted a survey including consecutive IBD patients initially in clinical and biochemical remission treated with biologics at the end of the first lockdown period. Patients underwent the normally scheduled clinical visits, performed at hospital for i.v.-treated patients or at home for patients treated with s.c. drugs. We administered to all patients the Hospital Anxiety and Depression Scale (HADS) questionnaire and other 12 questions, specifically related to COVID-19 and its implications. A total of 189 IBD patients were recruited, 112 (59.3%) treated with i.v. drugs and 77 (40.7%) with s.c. ones. No relapses were recorded in either group (hospitalized vs. non-hospitalized, p = ns), as well as which, COVID-19 infections were not demonstrated in patients in contact with people with suspected symptoms or directly experiencing them. The total HADS score obtained by the sum of all items was also almost identical between groups (37.1 ± 2.8 vs. 37.2 ± 2.8; p = 0.98). In patients treated with i.v. drugs receiving a televisit (n = 17), the rate of satisfaction with telemedicine (58.8%) was significantly lower compared with those treated with s.c. drugs (94.8%; p < 0.0005). Our results suggest that hospitalisation during the COVID-19 outbreak does not increase the risk of COVID-19 infection as well as the risk of IBD relapse; moreover, the similar levels of anxiety in both groups could confirm that there is no need to convert patients from i.v. to s.c. therapy.

Sign in / Sign up

Export Citation Format

Share Document